Role Of Non-Specific Effects in The Treatment of Depression With Esketamine
- Conditions
- Depressive Episode
- Interventions
- Behavioral: Pre and Post Treatment Presentations
- Registration Number
- NCT05910775
- Lead Sponsor
- Yale University
- Brief Summary
The investigators aim to examine the magnitude of non-specific effects in the treatment of depressive episodes with esketamine, by providing patients in the intervention group with a pretreatment presentation and post-treatment follow up session, to assess whether nonspecific effects can be used effectively to improve the effectiveness of treatment with esketamine.
- Detailed Description
Primary Objective:
To determine whether a positive presentation before first treatment improves expectation of improvement from treatment in patients receiving esketamine for a depressive episode within 24 hours after the first treatment.
Secondary Objectives:
To determine whether a post-treatment follow up session to provide encouragement and reassurance improves expectation of improvement from treatment in patients receiving esketamine for a depressive episode within 24 hours after the first treatment.
To determine whether a positive presentation results in an improved response from treatment in patients receiving esketamine for a depressive episode as measured by MADRS score within 24 hours after the first treatment.
To determine whether a positive presentation before first treatment, combined with a posttreatment follow up session after first treatment, result in an improved response from treatment in patients receiving esketamine for a depressive episode as measured by MADRS score by the end of the acute course of esketamine treatment.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
- Participants must be either male or female and at least 18 years old
- Deemed clinically appropriate to receive esketamine by a Yale Interventional Psychiatry physician.
- Written consent for the study procedures
- Ability and willingness, in the investigator's judgement, to comply with the study schedule, treatment plan, and other trial requirements for the duration of the study.
- Hearing or visual impairment to the degree that would interfere with ability to view the presentation
- Difficulty in understanding spoken or written English
- Unable to provide informed consent
- Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the presentation (per investigator judgment)
- Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study.
- Previous Esketamine or ketamine treatment
- Unable to give informed consent
- Was previously enrolled/randomized into the trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention + TAU Pre and Post Treatment Presentations Participants receive a presentation prior to the first treatment and receive a "follow up" session within 24 hours after the first treatment in addition to treatment as usual
- Primary Outcome Measures
Name Time Method Group difference in change in question 6 score on Treatment Credibility and Expectancy Scale (CEQ-6) baseline and after presentation (before treatment 1), up to 30 days Participants' expectations will be assessed by the change in the group score of item 6 of the CEQ-6 at baseline and after the presentation (before treatment 1). Item 6 is scored from 0% (not at all) to 100% (very much). Higher scores indicates expectations have been met.
- Secondary Outcome Measures
Name Time Method Group difference in change in Montgomery-Åsberg Depression Rating Scale (MADRS) score baseline and within 24 hours post treatment 1 MADRS score will be used to assess whether a positive presentation results in an improved response from treatment in participants receiving esketamine for a depressive episode within 24 hours after the first treatment. MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes. Each item is rated on a 0-6 scale, resulting in a maximum total score of 60 points, with higher scores indicative of greater depressive symptomology.
Trial Locations
- Locations (1)
Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit
🇺🇸New Haven, Connecticut, United States